Intellectual Product
Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges
Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination
Novo Nordisk and Viatris Settle Patent Dispute Over Ozempic and Wegovy, Keeping Generic Entry Date Undisclosed
Novo Nordisk, Viatris, Mylan Pharmaceuticals, Ozempic, Wegovy, Patent Dispute, Generic Entry Date, Settlement Agreement
Scholar Rock’s Stock Skyrockets 300% Following Successful Phase III Trial of Apitegromab for Spinal Muscular Atrophy
Scholar Rock, Spinal Muscular Atrophy (SMA), Apitegromab, Phase III Trial, Stock Surge, Biologics License Application (BLA), Marketing Authorisation Application (MAA)
BIOSECURE Act: Navigating Industry Implications and Future Directions
BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
Pfizer Generates $2.88 Billion by Selling Off Hundreds of Millions of Haleon Shares
Pfizer, Haleon, share sale, pharmaceutical industry, financial news
Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%
Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody
UK Regulator Approves Pharming’s Joenja for Rare Immune Disorder APDS, Leveraging FDA Review
Joenja, leniolisib, APDS, MHRA approval, FDA review, rare immune disorder, Pharming
Emergent BioSolutions Secures $400 Million in Orders for Smallpox and Mpox Vaccines Amid Ongoing Outbreak
Emergent BioSolutions, smallpox, mpox, vaccine orders, biodefense, global health preparedness
Biohaven Achieves Breakthrough in Spinocerebellar Ataxia Treatment with Positive Pivotal Study Results for Troriluzole
Biohaven, Troriluzole, Spinocerebellar Ataxia (SCA), Pivotal Study Results, Neurodegenerative Disease, FDA Submission, New Drug Application (NDA)